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Abstract
Background: Community pharmacies have great potential to deliver services aimed at promoting health and
preventing disease, and are embedded within communities. In the light of a rapid increase in community
pharmacy-delivered public health services and an accompanying increase in the evidence base, this systematic
review of reviews will synthesise systematic reviews of public health community pharmacy interventions and assess
their effects on public health and health inequalities.
Methods/design: Systematic review methodology will be used to identify all systematic reviews that describe the
health and health equity effects of community pharmacy public health interventions. Twenty databases will be
searched using a pre-determined search strategy to evaluate community pharmacy-delivered public health
interventions. Findings from the included reviews will be pooled, and a narrative synthesis executed to identify
overarching patterns and results.
Discussion: Findings will support future decision-making around how community pharmacy public health services
can be used alongside other strategies to promote health, prevent disease and reduce health inequalities.
Systematic review registration: PROSPERO registration number: CRD42017056264.
Keywords: Community pharmacy, Prevention, Health promotion, Public health, Health and health inequalities,
Systematic review
Background
In recent years, community pharmacies have emerged as
strategically important settings that have great potential to
deliver services aimed at promoting health and preventing
disease. Indeed, community pharmacies have, globally,
been identified as an easily accessible and cost-effective
platform for delivering healthcare services [1]. For ex-
ample, in the UK, 89% of the population can reach a com-
munity pharmacy within 20 min and, crucially, in areas of
high deprivation, that value increases to approximately
100% of the population—an observation known as the
positive pharmacy care law [2]. In view of the wide acces-
sibility to healthcare (a well-established social determinant
of health), community pharmacies are ideally placed to
offer public health services to all communities, including
the most socio-economically deprived ones.
Considering this potential, the role of the community
pharmacist has undergone rapid expansion [3]. Indeed, in
addition to supplying medication, many community pharma-
cies now offer an abundance of patient-focussed public
health services. Smoking cessation services were one of the
earliest examples of such a service [4], but others, such as
improving general lifestyle behaviours, increasing uptake of
screening and giving sexual health advice, have since
followed. Accompanying this development, the evidence
base surrounding the extended role of the community
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pharmacist in public health has also expanded—with many
groups producing systematic reviews examining the effect-
iveness of such interventions.
Despite this progress, however, and in view of the
expanding literature base, the effects of community phar-
macy interventions on population health—and perhaps
more significantly, health inequalities—is still not clear.
While there are many reviews, which focus on particular
public health areas (e.g. [5] and [6]), these have not been
brought together to assess the overall effects of the variety
of community pharmacy interventions underway in the
public health arena or how they impact on inequalities in
health. It is, therefore, timely that we undertake a system-
atic review of reviews of community pharmacy services in
order to support policy-makers and commissioners in
their future decision-making around how community
pharmacy public health services can be used alongside
other strategies to promote health, prevent disease and re-
duce health inequalities.
Methods
A systematic review of reviews will be conducted. This
methodology is an established and effective way of bringing
together and summarising a broad evidence base [7] and
have been used for a number of public health topics [8–11].
Our review was designed using the Preferred Reporting
Items for Systematic Review and Meta-Analyses (PRISMA)
Guidelines [7]. A PRISMA-P checklist is available as an
Additional file 1 to this protocol. This protocol is registered
with PROSPERO (CRD42017056264).
Research question
What are the effects of community pharmacy-delivered pub-
lic health interventions on health and health inequalities?
Study design
Systematic review methodology will be used to locate, ap-
praise and synthesise published systematic review level
evidence on the effects of community pharmacy-delivered
interventions on health and inequalities in health [8–11].
Inclusion criteria
Following standard evidence synthesis approaches [12],
the inclusion criteria for the review are determined a
priori in terms of PICOS (population, intervention, com-
parison, outcome and setting [13]).
 Population: Children and adults (all ages) in any
country. The population is kept purposively broad to
allow the widest range of literature to be identified.
 Intervention: Public health interventions delivered
in community pharmacy settings. The inclusion
criteria are purposely broad to allow for a range of
different public health interventions to be located.
For the purposes of the review, a community
pharmacy was defined as a pharmacy set in the
community, which is accessible to all and not based
in a hospital, clinic or online [5].
 Comparison: We will include systematic reviews that
include studies with and without controls, including
randomised and nonrandomised controlled trials,
randomised and nonrandomised cluster trials,
prospective and retrospective cohort studies (with
and/or without control groups), prospective repeat
cross-sectional studies (with and/or without control
groups) and interrupted time series (with and/or with-
out control groups). Acceptable controls include ran-
domised or matched designs. Reviews assessing
qualitative studies will be excluded.
 Outcomes: Health and health inequality outcomes.
Reviews that do not assess effectiveness of
community pharmacy-delivered public health inter-
ventions will be excluded. Primary outcome mea-
sures will be conceptualised using the framework
proposed by Hardeman and colleagues [14] and in-
clude determinants of behaviour (e.g. self-efficacy,
perceived control), behavioural outcomes (e.g. smok-
ing cessation, improved physical activity), physiology
and biochemical outcomes (e.g. blood pressure,
plasma cholesterol) and health outcomes (e.g. inci-
dence rates of cardiovascular disease). Secondary
outcomes relate to health inequalities in terms of
PROGRESS-Plus factors: place of residence, race/
ethnicity, occupation, gender, religion, education,
socio-economic status (defined as individual income,
wealth, education, employment or occupational sta-
tus, benefit receipt; as well as area-level socio-
economic indicators), social capital, age, disability
and sexual orientation [15]. When available, cost ef-
fectiveness data will also be collected.
 Setting: Only systematic reviews will be included in
the analysis. Included publications will need to meet
the two mandatory criteria of Database of Abstracts of
Reviews of Effects (DARE): (i) that there is a defined
review question (with definition of at least two of, the
participants, interventions, outcomes or study designs)
and (ii) that the search strategy included at least one
named database, in conjunction with either reference
checking, hand-searching, citation searching or contact
with authors in the field. When two reviews are
identified with the same research aims (e.g. to assess
the effectiveness of community pharmacy smoking
cessation services), only the most recent review will be
synthesised as part of this study.
Search strategy
Twenty databases will be searched from inception until
January 2017 (host sites given in parentheses): Medline
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(Ovid), Embase (Ovid), Cumulative Index to Nursing and
Allied Health Literature (CINAHL; EBSCOhost), PsycINFO
(EBSCOhost), Social Science Citation Index (Web of Sci-
ence), Applied Social Sciences Index and Abstracts (ASSIA;
ProQuest), International Bibliography of the Social Sciences
(IBSS; ProQuest), Sociological Abstracts (ProQuest), Social
Services Abstracts (ProQuest), Prospero (Centre for Reviews
and Dissemination, University of York), Campbell Collabor-
ation Library of Systematic Reviews (The Campbell Library),
Cochrane Library (includes Cochrane Database of System-
atic Reviews, Cochrane Central Register of Controlled Tri-
als, Cochrane Methodology Register, Database of Abstracts
of Reviews of Effects, Health Technology Assessment Data-
base, NHS Economic Evaluation Database; Wiley), Database
of Promoting Health Effectiveness Reviews (DoPHER; EPPI-
Centre), Social Care Online (SCIE) and Health Systems Evi-
dence. The search strategies have been developed from two
previous systematic and umbrella review search strategies
[2, 11] and an example search strategy is shown for Medline
in Additional file 2. To ensure the sensitivity of the searches,
five articles [5, 6, 16–18] known to the authors that met the
inclusion criteria were identified. The search strategy was
piloted in each of the databases and all of the five articles
were retrieved. In addition, the bibliographies and reference
lists of all included articles will be searched for further rele-
vant publications. Searches will be limited to peer-reviewed
publications only. Reviews will not be excluded based on
language or publication date. If reviews are missing key in-
formation (e.g. information relating to study design or inter-
vention details), they will be excluded from further analysis;
however, attempts will be made to contact authors to obtain
any relevant information that is missing.
Screening, data extraction and quality appraisal
The initial screening of titles and abstracts will be con-
ducted in duplicate by one reviewer (FHB) using EndNote
reference management software (Thomson Reuters, Phila-
delphia, USA). A random 10% sample of titles and abstracts
will be double screened by a second reviewer (NW) and
inter-rater reliability will be assessed using the kappa statis-
tic. Any discrepancies will be resolved through discussion
between the two reviewers, and, if consensus is not reached,
with the project lead (AT). Full text copies of potentially
relevant articles will then be examined for inclusion by one
reviewer (FHB), and checked by a second reviewer (AT).
Data will be extracted by one reviewer (NW or MB) and
checked by a second (FHB), using standard data extraction
forms based on previous reviews [8, 11]. Any discrepancies
will be resolved through discussion between the two re-
viewers and the project lead (AT) if necessary. The follow-
ing data will be extracted: the intervention type reviewed;
the study population in the review (and in the included
studies); who delivered the intervention; study design of
studies included in the review (e.g. RCTs, controlled
prospective cohort, repeat cross sections); any time/lan-
guage/country/population restrictions in the review; the
number of relevant studies in review (total); number of
databases searched (total); whether grey literature was
searched or citation follow up conducted; the method of
synthesis (meta-analysis or narrative); any details on imple-
mentation of interventions contained within the review;
and the main findings both in terms of health and socio-
economic inequalities in health.
The methodological quality of each review will be deter-
mined using the Assessment of Multiple Systematic
Reviews (AMSTAR) [19], which will be included as part of
the data extraction form. The AMSTAR asks questions
on: ‘a priori’ design, duplicate study selection and data
extraction, literature search details, status of publications
included, included and excluded study reference lists,
characteristics of included studies, scientific quality of
included studies, methods of combining findings, assess-
ment of publication bias and conflict of interest. This is
now the most frequently recommended tool for use within
an systematic reviews of reviews, due to its ease of use and
external validation [10, 13]. The use of AMSTAR also al-
lows us to determine if the risk of bias was assessed in the
included reviews. Further to this, we will use the revised
version of AMSTAR (R-AMSTAR) to quantify the system-
atic review quality in terms of low, medium and high [20].
Synthesis
A narrative synthesis will be conducted following the Eco-
nomic and Social Research Council (ESRC) guidance, as
described by Popay and colleagues [21]. We shall examine
similarities and differences between findings of the in-
cluded reviews, using effect sizes where meta-analysis has
been conducted, and exploring patterns in narrative syn-
theses. Findings in terms of population level health effects
will be described, as well as health inequality implications
from any PROGRESS-Plus subgroup analyses reported.
We will also assess each systematic review to determine if
there are any overlapping studies. If overlapping studies
are found, when undertaking the synthesis, we will con-
sider systematic reviews that: (1) provide the most
complete description, (2) are the most recent, (3) contain
the most evidence and, (4) use the method that is the
most vigorous. Dealing with overlapping studies has been
acknowledged as a challenge when undertaking systematic
reviews of reviews, [22] but our proposed approach to deal
with such issues has been described previously [23]. Re-
view quality, strength of evidence, and risk of bias will be
considered in the interpretation of the findings, which is
often lacking in systematic reviews of reviews [24].
Discussion
This umbrella review will provide evidence how commu-
nity pharmacy public health interventions affect population
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health and health inequalities. In addition, we will also es-
tablish and highlight any gaps in the systematic review evi-
dence base around community pharmacy public health
interventions. We anticipate the findings of this review will
be used to by policy-makers and commissioners to inform
future public health services; the review will also be used by
academics to direct future research toward any evidence
gaps that we may highlight.
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